{"id":70799,"date":"2026-05-12T11:37:16","date_gmt":"2026-05-12T11:37:16","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70799"},"modified":"2026-05-13T12:36:38","modified_gmt":"2026-05-13T12:36:38","slug":"glow","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/glow\/","title":{"rendered":"GLOW Blend (BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Quick Answer \u2014 What is GLOW?<\/h3>\n<p style=\"margin: 0;\"><strong>GLOW<\/strong> is a co-formulated three-peptide blend combining <a href=\"https:\/\/medsbase.com\/nl\/bpc-157\/\">BPC-157<\/a> 10\u00a0mg, <a href=\"https:\/\/medsbase.com\/nl\/ghk-cu\/\">GHK-Cu<\/a> 50\u00a0mg, and <a href=\"https:\/\/medsbase.com\/nl\/tb-500\/\">TB-500<\/a> 10\u00a0mg in a single lyophilized vial. The combination covers three complementary regenerative mechanisms in one administration: BPC-157&#8217;s local angiogenic and growth-factor signalling, GHK-Cu&#8217;s copper-mediated dermal remodelling, and TB-500&#8217;s systemic G-actin-binding tissue migration. Each vial contains 70\u00a0mg of total peptide for laboratory research use only.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Wat u krijgt bij MedsBase:<\/strong> Research-grade lyophilized peptide blend \u00b7 HPLC \u226599% purity (each component, COA on request) \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide peptide courier \u00b7 1,400+ verified <a href=\"https:\/\/medsbase.com\/nl\/reviews\/\">klantbeoordelingen<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Elke bestelling is gedekt door onze <a href=\"https:\/\/medsbase.com\/nl\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specificatie<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Composition<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">BPC-157 10\u00a0mg + GHK-Cu 50\u00a0mg + TB-500 10\u00a0mg per vial (1:5:1 mass ratio, co-formulated)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Total Peptide per Vial<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">70\u00a0mg total peptide mass<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Component CAS Numbers<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">137525-51-0 (BPC-157) \/ 49557-75-7 (GHK-Cu) \/ 77591-33-4 (TB-500 \/ thymosin beta-4)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mechanism Profile<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">VEGF-mediated angiogenesis (BPC-157) + copper-mediated dermal remodelling (GHK-Cu) + G-actin-binding systemic tissue migration (TB-500) \u2014 three complementary regenerative pathways<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Form<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized co-formulated powder (light blue tint from bound Cu<sup>2+<\/sup>)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Zuiverheid<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (each component HPLC verified, COA on request)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Opslag<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofiliseerd: 2\u20138 \u00b0C (koelkast) voor werkvoorraad; \u221220 \u00b0C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2\u20138 \u00b0C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Oplosbaarheid<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bacteriostatic water (recommended). All three peptides reconstitute simultaneously from the same vial; the reconstituted solution should retain a faint blue tint from the bound Cu<sup>2+<\/sup> of GHK-Cu.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Onderzoeksgebruik<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Alleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>What Is GLOW?<\/h2>\n<p><strong>GLOW<\/strong> is a research-grade co-formulated three-peptide blend that combines <a href=\"https:\/\/medsbase.com\/nl\/bpc-157\/\">BPC-157<\/a> (Body Protection Compound 157), <a href=\"https:\/\/medsbase.com\/nl\/ghk-cu\/\">GHK-Cu<\/a> (Glycyl-Histidyl-Lysine Copper(II) complex), and <a href=\"https:\/\/medsbase.com\/nl\/tb-500\/\">TB-500<\/a> (Thymosin Beta-4 fragment) in a single lyophilized vial at a 1:5:1 mass ratio \u2014 10\u00a0mg BPC-157, 50\u00a0mg GHK-Cu, and 10\u00a0mg TB-500 per vial, for a total of 70\u00a0mg peptide mass. The three peptides represent three of the most cited regenerative-research compounds in the published literature, each acting on a different molecular axis: BPC-157 on local angiogenesis and growth-factor signalling, GHK-Cu on copper-mediated dermal remodelling and antioxidant signalling, and TB-500 on systemic G-actin-binding and cell migration.<\/p>\n<p>The strategic rationale for the GLOW blend is <strong>complementary, non-overlapping mechanisms<\/strong> across three regenerative axes. Each component peptide has a distinct molecular target and tissue-distribution pattern, so co-administration covers a broader range of research endpoints than any single component alone. The blend is intended for research that benefits from simultaneous activation of all three pathways \u2014 a use case distinct from research designs that require independent dosing of each component peptide.<\/p>\n<p>For research that needs <strong>independent dosing<\/strong> of each peptide (different doses, different schedules, different vehicle formulations), the components are also available as stand-alone vials: <a href=\"https:\/\/medsbase.com\/nl\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/nl\/ghk-cu\/\">GHK-Cu<\/a>, en <a href=\"https:\/\/medsbase.com\/nl\/tb-500\/\">TB-500<\/a>. A separate three-vial bundle \u2014 the <a href=\"https:\/\/medsbase.com\/nl\/peptide-healing-stack\/\">Peptide Healing Stack<\/a> (BPC-157 + TB-500 + bacteriostatic water shipped together as three separate vials) \u2014 provides another alternative for research requiring per-component dose-flexibility. The GLOW co-formulation is specifically for research at the fixed 1:5:1 mass ratio with single-vial reconstitution.<\/p>\n<p>GLOW is supplied as a high-purity lyophilized blend for reconstitution with bacteriostatic water. The reconstituted solution retains a faint blue tint from the bound Cu<sup>2+<\/sup> of the GHK-Cu component \u2014 a useful qualitative indicator that copper coordination remained intact through lyophilization and reconstitution. GLOW is <strong>niet goedgekeurd<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a combination or as any of its component peptides. The research-grade GLOW sold here is supplied <strong>uitsluitend voor laboratoriumonderzoek<\/strong> and is not intended for human or veterinary administration.<\/p>\n<h2>Mechanism of Action \u2014 Three Complementary Regenerative Pathways<\/h2>\n<p>What makes the GLOW co-formulation pharmacologically distinctive is the <strong>tri-axis mechanism profile<\/strong> \u2014 each component activates a fundamentally different regenerative pathway, and the three are non-overlapping at the molecular level. Published research on each component has established the mechanism in detail; the combination simply delivers all three in a single administration:<\/p>\n<ul>\n<li><strong>BPC-157 (10\u00a0mg) \u2014 VEGF \/ NO \/ GH-receptor signalling for local tissue repair<\/strong> \u2014 The 15-amino-acid pentadecapeptide derived from gastric juice upregulates VEGFR2 (driving new capillary formation at injury sites), enhances endothelial nitric oxide synthase activity (protecting vascular endothelium), and increases growth-hormone receptor expression on fibroblasts and tenocytes (driving collagen synthesis). Most-cited research signal: tendon, ligament, gut barrier, and skeletal muscle recovery. Acts more locally than systemic at the injection site.<\/li>\n<li><strong>GHK-Cu (50\u00a0mg) \u2014 copper-mediated dermal remodelling and antioxidant signalling<\/strong> \u2014 The Cu<sup>2+<\/sup>-coordinated tripeptide delivers copper as an enzyme cofactor for lysyl oxidase (collagen\/elastin cross-linking) and superoxide dismutase (oxidative-stress buffering) while signalling on dermal fibroblasts and keratinocytes. Most-cited research signal: skin remodelling, wound healing, anti-aging in connective-tissue research, hair follicle support, copper-axis pharmacology. Higher mass loading (50\u00a0mg in the blend) reflects the larger doses typical of copper-peptide research vs the microgram-range doses of the other two components.<\/li>\n<li><strong>TB-500 (10\u00a0mg) \u2014 G-actin sequestration and systemic cell migration<\/strong> \u2014 The 43-amino-acid thymic peptide is the canonical systemic regenerative compound, binding monomeric G-actin and modulating actin dynamics to drive cell migration, particularly at injury sites. Most-cited research signal: systemic muscle and cardiac recovery, vascular repair, and broad systemic distribution that complements BPC-157&#8217;s more localised action. Acts as the &#8220;systemic arm&#8221; to BPC-157&#8217;s &#8220;local arm&#8221;.<\/li>\n<\/ul>\n<p>The three pathways are <strong>mechanistically complementary<\/strong>, not redundant: BPC-157 acts locally on the injury site, TB-500 distributes systemically and supports cell migration globally, and GHK-Cu provides copper-cofactor delivery and dermal-tissue-specific signalling. Co-administering the three in research models covers angiogenesis (BPC-157), systemic recovery (TB-500), and dermal-tissue remodelling (GHK-Cu) simultaneously \u2014 a broader research endpoint coverage than any single component alone. All three peptides have well-tolerated profiles in published preclinical research, and combination protocols are described in some published research models of multi-axis tissue regeneration.<\/p>\n<h2>Gepubliceerde onderzoeksapplicaties<\/h2>\n<p>GLOW co-formulation research is used in laboratory contexts that investigate:<\/p>\n<ul>\n<li><strong>Multi-axis tissue regeneration research<\/strong> \u2014 preclinical models combining systemic and local regenerative endpoints; angiogenesis + cell migration + dermal remodelling in single research designs<\/li>\n<li><strong>Wound healing research<\/strong> \u2014 cutaneous wound models (full-thickness, partial-thickness, burn), wound contraction kinetics, granulation tissue formation, scar-tissue characterisation; one of the more comprehensive multi-axis approaches<\/li>\n<li><strong>Tendon, ligament, and soft-tissue recovery<\/strong> \u2014 rodent Achilles transection models, medial-collateral-ligament rupture research; published BPC-157 + TB-500 research literature is extensive, with the GHK-Cu addition providing copper-cofactor support for collagen cross-linking<\/li>\n<li><strong>Skin remodelling and dermal research<\/strong> \u2014 collagen and elastin synthesis, dermal-fibroblast proliferation, photo-aging research; the GHK-Cu component dominates this research domain<\/li>\n<li><strong>Comparative co-formulation research<\/strong> \u2014 head-to-head with stand-alone <a href=\"https:\/\/medsbase.com\/nl\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/nl\/tb-500\/\">TB-500<\/a>, en <a href=\"https:\/\/medsbase.com\/nl\/ghk-cu\/\">GHK-Cu<\/a> arms; dissection of additive vs synergistic effects across the three-axis combination<\/li>\n<li><strong>Vascular and cardiac recovery research<\/strong> \u2014 the combined angiogenic (BPC-157) and migratory (TB-500) signal is well-suited to vascular-recovery and cardiac-ischaemia models<\/li>\n<li><strong>Anti-aging and longevity research<\/strong> \u2014 published work on copper-peptide effects in dermal and connective-tissue aging, particularly relevant for the GHK-Cu component; combined with BPC-157 + TB-500 for broader tissue-aging research designs<\/li>\n<li><strong>Inflammation and oxidative-stress research<\/strong> \u2014 copper&#8217;s role as cofactor for superoxide dismutase plus the BPC-157 and TB-500 inflammation-modulating effects provide multi-axis anti-inflammatory research coverage.<\/li>\n<\/ul>\n<p>For broader context, see our individual <a href=\"https:\/\/medsbase.com\/nl\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/nl\/ghk-cu\/\">GHK-Cu<\/a>, en <a href=\"https:\/\/medsbase.com\/nl\/tb-500\/\">TB-500<\/a> product pages for component-level pharmacology, the <a href=\"https:\/\/medsbase.com\/nl\/peptide-healing-stack\/\">Peptide Healing Stack<\/a> for the alternative three-separate-vial bundle (BPC-157 + TB-500 + bacteriostatic water), and the sister copper peptide <a href=\"https:\/\/medsbase.com\/nl\/ahk-cu\/\">AHK-Cu<\/a> for hair-axis research. Browse the full <a href=\"https:\/\/medsbase.com\/nl\/peptides\/\">onderzoekspeptiden catalogus<\/a> voor gerelateerde verbindingen.<\/p>\n<h2>Available Configurations<\/h2>\n<p>MedsBase stocks the GLOW blend in a single co-formulation: <strong>10\u00a0mg BPC-157 + 50\u00a0mg GHK-Cu + 10\u00a0mg TB-500 per vial<\/strong> (1:5:1 mass ratio, 70\u00a0mg total peptide). The vial is available in 10-vial or 20-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Vial Composition<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typisch Onderzoeksgebruik<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Verpakkingsgroottes<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg BPC-157 + 50 mg GHK-Cu + 10 mg TB-500<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard tri-axis regenerative-research blend \u2014 angiogenesis + dermal remodelling + systemic cell migration in single administration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 of 20 flesjes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three components are supplied at \u226599% HPLC purity (each verified individually) and pre-mixed in the same lyophilized vial. Because the three peptides have different research dose ranges and different roles in the blend, the 1:5:1 mass ratio is fixed at manufacture. Researchers requiring different ratios should use the stand-alone <a href=\"https:\/\/medsbase.com\/nl\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/nl\/ghk-cu\/\">GHK-Cu<\/a>, en <a href=\"https:\/\/medsbase.com\/nl\/tb-500\/\">TB-500<\/a> vials instead. Compared with purchasing the three components separately, the GLOW co-formulation offers a meaningful cost saving and the practical convenience of single-vial reconstitution at the fixed research ratio.<\/p>\n<h2>How It Compares \u2014 GLOW Blend vs Peptide Healing Stack<\/h2>\n<p>MedsBase carries two multi-peptide research products that combine the same broader healing-peptide pharmacology in different packaging formats. The choice between them depends on research design requirements:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GLOW Blend<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\"><a href=\"https:\/\/medsbase.com\/nl\/peptide-healing-stack\/\">Peptide Healing Stack<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Packaging format<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Single vial, co-formulated<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Three separate vials shipped together<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Composition<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BPC-157 10\u00a0mg + GHK-Cu 50\u00a0mg + TB-500 10\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BPC-157 5\u00a0mg + TB-500 5\u00a0mg + Bacteriostatic Water<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Component count<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Three peptides (adds copper peptide)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Two peptides + diluent (no copper peptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose flexibility<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fixed 1:5:1 mass ratio per vial<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Per-component dose independence<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Reconstitution<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Single reconstitution event<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Per-vial reconstitution<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Use case<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Convenience + fixed-ratio research; broader 3-axis coverage including dermal remodelling<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dose-flexible research; classic 2-axis healing focus (BPC + TB only)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Research designs that require flexible per-component dosing or that don&#8217;t need the copper-peptide arm should use the <a href=\"https:\/\/medsbase.com\/nl\/peptide-healing-stack\/\">Peptide Healing Stack<\/a>. Research designs that benefit from the broader three-axis coverage (including dermal-tissue remodelling) and that are comfortable with the fixed 1:5:1 mass ratio should use the GLOW blend. Both options are pre-curated for the most-cited healing-peptide research pharmacology \u2014 the difference is packaging format and component breadth.<\/p>\n<h2>Opslag en Reconstituering<\/h2>\n<p><strong>Voor reconstituering:<\/strong> store lyophilized vials refrigerated at 2\u20138\u00a0\u00b0C in original packaging for short-term working stock. For unopened long-term storage, freeze at \u221220\u00a0\u00b0C. The lyophilized GLOW co-formulation is stable under refrigeration for up to 24 months and at \u221220\u00a0\u00b0C for up to 36 months. All three component peptides have well-matched stability profiles in the lyophilized state. Avoid freeze-thaw cycles on the lyophilized powder.<\/p>\n<p><strong>Reconstitueringsprocedure:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). Because the vial contains 70\u00a0mg total peptide mass, a 2.0\u00a0mL reconstitution yields a 35\u00a0mg\/mL total-peptide working concentration \u2014 equivalent to 5\u00a0mg\/mL BPC-157, 25\u00a0mg\/mL GHK-Cu, and 5\u00a0mg\/mL TB-500. Swirl gently \u2014 do <strong>niet<\/strong> shake \u2014 and allow 2\u20135 minutes for full dissolution. A correctly reconstituted solution should be clear with a <strong>faint blue tint<\/strong> from the bound Cu<sup>2+<\/sup> of the GHK-Cu component \u2014 the colour is a useful qualitative indicator that copper coordination remained intact through lyophilization and reconstitution. Cloudiness, precipitate, or absent blue tint indicates a problem; discard and try again.<\/p>\n<p><strong>Na reconstitutie:<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability of all three components. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity and can affect copper coordination. Protect from direct light at all times. Discard any vial showing cloudiness, precipitate, or discolouration beyond the expected faint blue tint.<\/p>\n<h2 id=\"faqs\">Veelgestelde vragen<\/h2>\n<h3>What is GLOW used for in research?<\/h3>\n<p>GLOW is used in laboratory research investigating multi-axis tissue regeneration \u2014 specifically protocols that benefit from simultaneous activation of three complementary regenerative pathways (BPC-157 angiogenesis + GHK-Cu dermal remodelling + TB-500 systemic cell migration) in a single administration. Common research contexts include wound healing models, tendon and soft-tissue recovery, skin remodelling, vascular repair, anti-aging connective-tissue research, and comparative co-formulation pharmacology. The research-grade GLOW sold here is <strong>niet<\/strong> FDA-goedgekeurd en wordt strikt geleverd voor laboratoriumonderzoek alleen.<\/p>\n<h3>What is in a GLOW vial?<\/h3>\n<p>Each vial contains <strong>10\u00a0mg of BPC-157, 50\u00a0mg of GHK-Cu, and 10\u00a0mg of TB-500<\/strong>, co-formulated and lyophilized together as a single powder. Total peptide mass per vial: 70\u00a0mg. The 1:5:1 mass ratio reflects the different research-relevant dose ranges of the three components (BPC-157 and TB-500 are used in microgram-to-low-milligram doses; GHK-Cu is used in low-to-mid-milligram doses). All three peptides reconstitute simultaneously when bacteriostatic water is added.<\/p>\n<h3>How is GLOW different from the Peptide Healing Stack?<\/h3>\n<p>The two products combine related healing peptides but in different packaging formats. <strong>GLOW<\/strong> is a single vial with three peptides (BPC-157 + GHK-Cu + TB-500) co-formulated together at a fixed 1:5:1 ratio. The <a href=\"https:\/\/medsbase.com\/nl\/peptide-healing-stack\/\">Peptide Healing Stack<\/a> is three separate vials (BPC-157 + TB-500 + bacteriostatic water) shipped in one parcel. GLOW adds the copper-peptide arm and consolidates reconstitution; the Peptide Healing Stack offers per-component dose independence without the copper-peptide component. Choose based on whether your research needs the dermal-remodelling axis (GLOW) or per-component dose flexibility (Peptide Healing Stack).<\/p>\n<h3>How is GLOW different from the individual component peptides?<\/h3>\n<p>The components are also available as stand-alone products: <a href=\"https:\/\/medsbase.com\/nl\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/nl\/ghk-cu\/\">GHK-Cu<\/a>, en <a href=\"https:\/\/medsbase.com\/nl\/tb-500\/\">TB-500<\/a>. Stand-alone vials allow per-component dose control, different schedules per peptide, and different vehicle formulations per peptide. The GLOW co-formulation fixes the dose ratio at 1:5:1 mass but offers convenience (single reconstitution, single injection) and modest cost savings compared with buying the three components separately.<\/p>\n<h3>What is the typical GLOW research dose?<\/h3>\n<p>Dose depends on the research endpoint. Conservative protocols use 0.04\u00a0mL of a 35\u00a0mg\/mL reconstituted solution (~200\u00a0mcg BPC-157 + 1\u00a0mg GHK-Cu + 200\u00a0mcg TB-500 per administration) several times weekly. Higher-dose protocols scale up proportionally within the fixed 1:5:1 ratio. Researchers requiring different ratios should use the stand-alone components rather than the blend.<\/p>\n<h3>Is GLOW FDA approved?<\/h3>\n<p>No. GLOW is not approved by the FDA, EMA, MHRA, or any other major regulator as a combination product. None of the three individual components (BPC-157, GHK-Cu, TB-500) have FDA approval for human therapeutic use either. GHK-Cu is incorporated into some cosmetic products under cosmetic-regulation frameworks, but none of the three peptides is approved as a drug. All GLOW sold by research-use-only suppliers is for laboratory investigation and should not be administered to humans.<\/p>\n<h3>Why does the GLOW solution have a blue tint?<\/h3>\n<p>The faint blue tint comes from the bound Cu<sup>2+<\/sup> of the GHK-Cu component \u2014 specifically from the d-d electronic transitions of copper in the square-planar coordination environment created by the Gly-His-Lys tripeptide. The colour is a useful qualitative indicator of intact copper coordination: a properly reconstituted GLOW solution should show a faint visible blue tint; a colourless or pale solution would suggest copper loss or degradation of the GHK-Cu component. The other two peptides (BPC-157, TB-500) contribute no colour.<\/p>\n<h3>How should GLOW be stored?<\/h3>\n<p>Lyophilized vials: refrigerated at 2\u20138\u00a0\u00b0C for short-term working stock, or \u221220\u00a0\u00b0C for long-term storage of unopened vials. Reconstituted solution: refrigerated at 2\u20138\u00a0\u00b0C, use within 30 days. Do not freeze reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity and could disproportionately affect either copper coordination or peptide-backbone stability. Protect from direct light at all times.<\/p>\n<h3>How do I reconstitute GLOW?<\/h3>\n<p>Volg de hierboven beschreven reconstitutieprocedure. Voeg bacteriostatisch water toe langs de zijkant van het flesje (niet rechtstreeks op het gevriesdroogde poeder), draai voorzichtig en laat 2\u20135 minuten staan voor volledige oplossing. Schud <strong>niet<\/strong> shake the vial. All three peptides reconstitute simultaneously from the same vial. A correctly reconstituted solution is clear with a faint blue tint. For a vial + 2.0\u00a0mL diluent, the working concentration is 5\u00a0mg\/mL BPC-157, 25\u00a0mg\/mL GHK-Cu, and 5\u00a0mg\/mL TB-500.<\/p>\n<h3>What configurations does MedsBase stock?<\/h3>\n<p>MedsBase carries GLOW in a single co-formulation: 10\u00a0mg BPC-157 + 50\u00a0mg GHK-Cu + 10\u00a0mg TB-500 per vial (70\u00a0mg total peptide, 1:5:1 mass ratio, lyophilized). The vial is available in 10-vial or 20-vial pack sizes. Each component is verified individually at \u226599% HPLC purity with a certificate of analysis available on request.<\/p>\n<h3>Can I buy GLOW components separately instead?<\/h3>\n<p>Yes \u2014 MedsBase stocks all three component peptides as stand-alone products: <a href=\"https:\/\/medsbase.com\/nl\/bpc-157\/\">BPC-157<\/a> in 2\/5\/10\u00a0mg vials, <a href=\"https:\/\/medsbase.com\/nl\/ghk-cu\/\">GHK-Cu<\/a>, en <a href=\"https:\/\/medsbase.com\/nl\/tb-500\/\">TB-500<\/a> in 2\/5\/10\u00a0mg vials. Separate vials are useful if research protocols require dose ratios other than the fixed 1:5:1 GLOW ratio, or if researchers want different scheduling per peptide. The co-formulated GLOW blend offers convenience and cost savings for research at the 1:5:1 ratio.<\/p>\n<h3>Does GLOW cause side effects in research?<\/h3>\n<p>All three component peptides have well-tolerated profiles in published preclinical research at typical research doses. The most consistent finding for the combination is the same as for the individual components: local injection-site reactions, occasional flushing at higher doses, and (rarely) modest skin discolouration at the injection site from copper deposition (from the GHK-Cu component). Systemic adverse effects are uncommon in published preclinical literature for any of the three peptides.<\/p>\n<h3>How long does GLOW take to show effects in preclinical research?<\/h3>\n<p>Effect onset varies by research endpoint. Local wound-healing and tissue-recovery effects are typically measurable within 7\u201314 days of regular dosing. Skin-remodelling effects (collagen synthesis, dermal-fibroblast activity) accumulate over 4\u20138 weeks. Systemic regenerative effects mediated by TB-500 develop over similar timescales. The combined three-axis profile produces a broader endpoint coverage than any single component, but the kinetics for each axis follow the timeline of the respective component peptide.<\/p>\n<h3>Can I order GLOW for international shipping?<\/h3>\n<p>Yes. MedsBase ships GLOW worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our <a href=\"https:\/\/medsbase.com\/nl\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Tissue Regeneration, Wound Healing, and Recovery Research<\/h2>\n<ul>\n<li><a href=\"\/nl\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Body Protection Compound \u2014 the local angiogenesis component of GLOW, stand-alone vials<\/li>\n<li><a href=\"\/nl\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Copper tripeptide \u2014 the dermal remodelling component of GLOW, stand-alone vials<\/li>\n<li><a href=\"\/nl\/tb-500\/\"><strong>TB-500 (Thymosin Beta-4)<\/strong><\/a> \u2014 Systemic healing fragment \u2014 the systemic cell migration component of GLOW<\/li>\n<li><a href=\"\/nl\/peptide-healing-stack\/\"><strong>Peptide Healing Stack<\/strong><\/a> \u2014 Alternative three-vial bundle (BPC + TB + BAC water) without copper peptide<\/li>\n<li><a href=\"\/nl\/ahk-cu\/\"><strong>AHK-Cu<\/strong><\/a> \u2014 Sister copper peptide to GHK-Cu \u2014 hair follicle research compound<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Verder lezen<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the regenerative-peptide research landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Bekijk het volledige <a href=\"https:\/\/medsbase.com\/nl\/peptides\/\"><strong>onderzoekspeptiden catalogus<\/strong><\/a>, with related regenerative compounds including <a href=\"https:\/\/medsbase.com\/nl\/bpc-157\/\">BPC-157<\/a> (local angiogenesis), <a href=\"https:\/\/medsbase.com\/nl\/tb-500\/\">TB-500<\/a> (systemic cell migration), <a href=\"https:\/\/medsbase.com\/nl\/ghk-cu\/\">GHK-Cu<\/a> (dermal remodelling), and the alternative <a href=\"https:\/\/medsbase.com\/nl\/peptide-healing-stack\/\">Peptide Healing Stack<\/a> bundle.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Three-peptide co-formulated regenerative blend<br \/>\n\u2705 BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg)<br \/>\n\u2705 Local angiogenesis + dermal remodelling + systemic cell migration<br \/>\n\u2705 Single vial, single reconstitution<br \/>\n\u2705 70mg total peptide per vial<\/p>\n<p><strong>GLOW<\/strong> is a co-formulated peptide blend.<\/p>","protected":false},"featured_media":70957,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5440,5449,6291,5441,5442],"class_list":{"0":"post-70799","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-bpc-157","8":"product_tag-ghk-cu","9":"product_tag-glow","10":"product_tag-peptide","11":"product_tag-tb-500","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product\/70799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/comments?post=70799"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media\/70957"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media?parent=70799"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_brand?post=70799"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_cat?post=70799"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_tag?post=70799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}